Associazione Qol-one Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT02912208
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Associazione Qol-one

Active Ingredients

Drugs in Phase 2 Trials (2)

eltrombopag (promacta) (2 trials)

lenalidomide (revlimid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2